CHRS: Pipeline advances and commercial execution position for growth, with major data readouts ahead
The conference highlighted a robust oncology pipeline targeting immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple indications. Key data readouts are expected in the coming months, supporting both revenue and clinical expansion.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.